Serum osteopontin can improve papillary thyroid cancer risk assessment of Bethesda III thyroid nodules: a preliminary study
Endocrine Oncology · 2021
DOI: 10.1530/eo-21-0005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Oncology, 2021. Verfasst von T U Kars und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Necmettin Erbakan University Meram School of Medicine, Konya, Turkey. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Thyroid cancer can be detected in 5–10% of patients with thyroid nodules. Management may be a challenge if fine-needle aspiration biopsy yields Bethesda III findings. Most of these cases undergo surgery and are ultimately found benign. Our aim was to evaluate whether serum osteopontin can accurately estimate thyroid cancer risk in cases with cytologically Bethesda III thyroid nodules and, thereby, decrease the number of unnecessary surgical interventions. Design and Methods We obtained blood samples of cases with repeated cytologically Bethesda III thyroid nodules before surgery, and followed up the pathology results after thyroidectomy. We evaluated serum osteopontin from 36 patients with papillary thyroid cancer and compared them with 40 benign cases.
Results
Serum osteopontin levels in patients with papillary thyroid cancer are significantly higher than in benign cases (mean serum osteopontin: 10.48 ± 3.51 ng/mL vs6.14 ± 2.29 ng/mL, P < 0.001). The area under the receiver operating characteristics curve was 0.851, suggesting that serum osteopontin could have considerable discriminative performance.
Conclusions
In our preliminary study, high serum osteopontin levels can predict the risk of papillary thyroid cancer in thyroid nodules with Bethesda III cytology. Further studies are necessary to confirm these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Necmettin Erbakan University Meram School of Medicine, Konya, Turkey.
- Division of Endocrinology and Metabolism Disease, Department of Internal Medicine, Necmettin Erbakan University Meram School of Medicine, Meram, Konya, Turkey.
- Department of Biochemistry, Necmettin Erbakan University Meram School of Medicine, Meram, Konya, Turkey.
Zitieren
APA
Kars, T. U., Kulaksızoğlu, M., & Kılınç, I. (2021). Serum osteopontin can improve papillary thyroid cancer risk assessment of Bethesda III thyroid nodules: a preliminary study. Endocrine Oncology. https://doi.org/10.1530/eo-21-0005
Vancouver
Kars TU, Kulaksızoğlu M, Kılınç I. Serum osteopontin can improve papillary thyroid cancer risk assessment of Bethesda III thyroid nodules: a preliminary study. Endocrine Oncology. 2021. doi:10.1530/eo-21-0005
BibTeX
@article{Kars2021,
author = {Kars, T U and Kulaksızoğlu, M and Kılınç, I},
title = {Serum osteopontin can improve papillary thyroid cancer risk assessment of Bethesda III thyroid nodules: a preliminary study},
journal = {Endocrine Oncology},
year = {2021},
doi = {10.1530/eo-21-0005}
}
EUVIMED